1 i3Innovus, Medford, MA, USA, 2 AMGEN, Thousand Oaks, CA, USA OBJECTIVES: Relative dose intensity (RDI) is generally defined as a patient's actual received chemotherapy dose over time period versus the intended dose over time where RDI <85% can be considered sub-optimal. Published cost-effectiveness analyses of febrile neutropenia (FN) prophylaxis modeled RDI assuming a fixed percentage of patients achieve low RDI. The objective of this study was to model the reasons for low RDI explicitly and evaluate the effects on results. METHODS: A lifetime Markov model of FN prophylaxis in the treatment of stage II breast cancer using TAC (FN risk ≥20%) and AC-T (FN risk <20%) chemotherapy was developed. Three FN prophylaxis strategies were compared: primary prophylaxis with pegfilgrastim (PPP), or with 6-day filgrastim (6D-PPF), and no prophylaxis (NP). RDI is modeled under two different scenarios: "fixed rate" where fixed proportion of patients receives low RDI and "flexible rate" where low RDI is function of chemotherapy-specific discontinuation and dose delay/reduction due to FN or other adverse events. Total costs and quality adjusted life years (QALYS) are accumulated in the model and results are reported in terms of incremental cost-effectiveness ratios (ICERs). All model parameters are estimated from published literature or expert opinion. RESULTS: In the TAC fixed rate scenario, results demonstrate that PPP dominates (less costly and more effective) both 6D-PPF and NP. In TAC flexible scenario, PPP also dominates both 6D-PPF and NP. In AC-T there is more variation in results; In the fixed rate scenario, PPP weakly dominates 6D-PPF, and the ICER versus NP is $106,700 per QALY gained, in the AC-T flexible scenario the ICER is $54,800 per QALY gained versus NP. CONCLUSIONS: Explicitly modeling discontinuations and dose delay/reductions can substantially affect model ICERS and subsequent willingess-to-pay interpretation, especially in lower-risk regimens. Furthermore, explicit modeling permits the flexibility to examine the effects of each factor alone. Total cost for each patient was the sum of inpatient and outpatient service costs. Inpatient cost was measured using resource intensity weights from the Canadian Institute of Health Information (CIHI) Discharge Abstract Database and standard average inpatient cost per weighted case in fiscal year. Outpatient cost was measured using encounter codes from the CIHI National Ambulatory Care Reporting System and the standard cost per encounter code from the Ontario Case Costing Initiative. The Ontario Health Insurance Plan Schedule of Physician Fees provided physician costs. Costs were adjusted for inflation, discounted at 5% per year, and reported in 2007 Canadian dollars. Statistical significance, set at p < 0.05, was tested using chi-square and ANOVA. RESULTS: Costs were measured for 66 BFM (41 standard-and 25 highrisk) and 28 DFCI (19 standard-and 9 high-risk) patients. There was no significant difference between BFM and DFCI strategies in risk group proportions (p = 0.597). Mean total cost varied by risk group (p = 0.029) but not overall strategy (p = 0.866). The BFM minus DFCI difference of mean total cost was $-12,679 (p = 0.336) for standard-risk patients, $29,576 (p = 0.140) for high-risk patients, and $2,725 (p = 0.777) for pooled risk patients. The mean total cost for pooled patients was $101,484 (SD = $38,296) for BFM and $98,760 (SD = $51,171) for DFCI. CONCLUSIONS: The incremental cost between the BFM and DFCI strategies was small and insignificant. Future analyses will focus on incremental treatment effectiveness of BFM and DFCI strategies: mean health-related quality of life utility scores during and after treatment; and quality-adjusted life years. treated CRC patients were identified between 2Q2005 and 4Q2007. The age distribution, the proportion of females, and the proportion receiving IV iron were similar between the groups. The EPO group had a lower mean (SD) Charlson Comorbidity Score [5.1(3.2)EPO; 5.5(3.2)DARB, P < 0.001]. Mean (SD) treatment duration was 1.9(1.1) quarters for EPO; 2.0(1.1) quarters for DARB (P value <0.001). Mean (SD) cumulative dose was 356,800(357,700)units for EPO; 1,371(1230)mcg for DARB. The observed dose ratio (EPO units/DARB mcg) was 260:1. ESA drug costs per treatment episode were $5,153 for EPO and $6,944 for DARB. Overall ESA drug costs were $1,791 higher (P < 0.001) for DARB, representing a 35% higher cost compared to EPO. CONCLU-SIONS: This study of Medicare CRC patients treated with ESA in the hospital outpatient setting observed 35% higher ESA drug costs in patients treated with DARB compared to EPO. (King, 2006), LAP allows reduction of 32% of the length-of-stay (LOS) for patients that underwent colectomy (9 days for OP vs. 6 days for LAP). A 7% conversion during the intervention from LAP to OP was considered since this was also reported (King, 2006) and confirmed by the opinion of specialists. An analytical decision model was built under a hospital standpoint. Only direct medical costs were considered. The base-case scenario assumed a full reimbursement scheme for devices (SIMPRO, 2009). For medical fees, ICU and in-patient costs, the CBHPM 5 th edition (Brazilian fee list) and the PROAHSA report were taken. Different LOS scenarios were simulated ranging from 8 days until 22 according to the literature review. A discount rate was not considered because the time horizon was shorter than one year. RESULTS: For patients that underwent OP the adoption of LAP would save from 2.6 days to 7 days. This reduction in LOS could generate cost opportunities ranging from R$80, for 2.6 days reduction to R$1270, for 7 days reduction. CONCLUSIONS: Findings suggest LAP allows a faster discharge of patients that underwent colon rectal surgery providing the hospital with the opportunity to reduce the LOS and, as a consequence, streamline both the use of both hospital facilities and other medical resources.
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PCN34 ECONOMIC BURDEN OF MYELODYSPLASTIC SYNDROMES AMONG US MEDICARE BENEFICIARIES: INCREASED COSTS IN TRANSFUSION DEPENDENT PATIENTS
Goldberg SL 1 , Chen E 2 , Corral M 3 , Guo A 4 , Laouri M 5 1 John Theurer Cancer Center, Hackensack, NJ, USA, 2 Quorum Consulting, San Francisco, CA, USA, 3 Novartis Oncology, East Hanover, NJ, USA, 4 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5 Quorum Consulting Inc, San Francisco, CA, USA OBJECTIVES: Previous studies have shown that patients with myelodysplastic syndromes (MDS) requiring blood transfusions are at increased risk of developing comorbidities. This study sought to determine the Medicare costs in the first 3 years following MDS diagnosis and evaluate whether blood transfusion dependent MDS patients incur additional costs. METHODS: A retrospective review of Medicare Standard Analytic Files was performed. Patients with ICD-9-CM code 238.7 in the first quarter of 2003, with no prior diagnosis of anemias of known causes or myeloid leukemia, were identified and followed until death or end of 2006. Health care resource use and total Medicare costs of MDS patients who received blood transfusion vs those who did not during the study period were compared. This timeframe predates the widespread use of "low intensity chemotherapy agents". RESULTS: 512 patients aged ≥65 years were diagnosed with MDS in the first quarter of 2003. 205 (40%) of these patients received blood transfusion during the study period. No significant differences were observed with respect to age, gender and race among transfused and non-transfused patients. Patients requiring transfusions had an increased prevalence of cardiac diseases, diabetes, dyspnea, hepatic disease and infections. During the 3-year follow-up, a higher percentage of transfused patients was hospitalized (91.2% vs. 67.1%, P < 0.001), admitted to emergency room (87.8% vs. 73.9%, P < 0.001), received growth factor treatments (59.5% vs. 26.4%, P < 0.001) and developed hemachromatosis (3.4% vs. 1.6%, P = 0.191) than non-transfused patients. Threeyear total Medicare costs were $88, 824 per transfused patient and $29,519 per non-transfused patient (p < 0.001). Hospital inpatient care and physician care constituted 43% and 31% of the total costs, respectively. CONCLUSIONS: MDS patients receiving transfusion were associated with end-organ impairment and incurred significantly higher Medicare costs than patients not receiving transfusions.
